For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website http://www.visiongain.com/Report/1223/Pharma-Leader-Series-Top-Stem-Cell-Technology-Companies-2014-2024

1. ©notice
This material is copyright by visiongain. It is against the law to reproduce any of this material without the prior written agreement of vision-
gain. You cannot photocopy, fax, download to database or duplicate in any other way any of the material contained in this report. Each pur-
chase and single copy is for personal use only.
Pharma Leader Series:
Top Stem Cell Technology Companies
2014-2024

2. www.visiongain.com
Contents
1.1 Top Stem Cell Technology Companies: Overview of Findings
1.2 Report Contents
1.3 Study Methods – Research and Analysis
1.4 Scope and Format of Report
2.1 Aastrom Biosciences
2.1.1 Stem Cell Technology Platform
2.1.2 Aastrom: Stem Cell Pipeline, 2014
2.1.2.1 Ixmyelocel-T: Patient-Specific Therapy Reduces Risk of Rejection
2.1.2.2 Orphan Designation to Accelerate Product Development
2.1.3 Sales and Recent Performance, 2012
2.1.4 Aastrom: Stem Cell SWOT Analysis, 2014-2024
2.1.5 Aastrom: Stem Cell Revenue Forecast, 2014-2024
2.2 Advanced Cell Technology (ACT)
2.2.1 Stem Cell Technology Platform
2.2.2 ACT: Stem Cell R&D Pipeline, 2014
2.2.2.1 Human Embryonic Stem Cells: Aiding Tissue Repair
2.2.3 Sales and Recent Performance, 2012
2.2.4 ACT: Stem Cell SWOT Analysis, 2014-2024
2.2.5 ACT: Stem Cell Revenue Forecast, 2014-2024
1. Executive Summary
2. Leading US Stem Cell Technology Companies, 2014

3. www.visiongain.com
Contents
2.3 Bioheart
2.3.1 Bioheart: Stem Cell Pipeline, 2014
2.3.2 Sales and Recent Performance, 2012
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
2.3.4.1 Increased Activity Abroad Will Help Bioheart Attract Investment
2.4 BrainStorm Cell Therapeutics
2.4.1 Brainstorm Cell Therapeutics: Stem Cell Pipeline, 2014
2.4.2 Brainstorm Cell Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.4.3 Brainstorm Cell Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.4.3.1 Government Grant Will Provide Much Needed Investment
2.5 California Stem Cell Inc.
2.5.1 California Stem Cell: Stem Cell Pipeline, 2014
2.5.2 California Stem Cell: Stem Cells SWOT Analysis, 2014-2024
2.6 International Stem Cell Corporation (ISCO)
2.6.1 ISCO: Stem Cell Pipeline, 2014
2.6.2 Sales and Recent Performance, 2012
2.6.3 ISCO: Stem Cells SWOT Analysis, 2014-2024
2.6.4 Cosmetic Subsidiary Expands Into Asian Market
2.7 NeoStem
2.7.1 NeoStem: Stem Cell Pipeline, 2014
2.7.1.1 AMR-001: Highly Efficacious Therapy for AMI
2.7.1.2 T-Cell Therapy: Using Autologous Immune Cells as Therapy
2.7.1.3 VSEL Technology: Promoting Cell Migration to Site of Damage
2.7.2 Sales and Recent Performance, 2012

4. www.visiongain.com
Contents
2.7.3 NeoStem: Stem Cell SWOT Analysis, 2014-2024
2.7.4 NeoStem: Stem Cell Revenue Forecast, 2014-2024
2.8 Neuralstem
2.8.1 Stem Cell Technology Platform
2.8.2 Neuralstem: Stem Cell Pipeline, 2014
2.8.2.1 NSI-566: Potential Therapy in Multiple Neurological Disorders
2.8.2.2 NSI-189: Deriving Cells from the Hippocampal Region
2.8.3 Sales and Recent Performance, 2012
2.8.4 Neuralstem: Stem Cell SWOT Analysis, 2014-2024
2.8.5 Neuralstem: Stem Cell Revenue Forecast, 2014-2024
2.9 Medistem
2.9.1 Medistem: Stem Cell Pipeline, 2014
2.9.2 Medistem: Stem Cell SWOT Analysis, 2014-2024
2.9.3 Medistem: Stem Cell Revenue Forecast, 2014-2024
2.9.3.1 Expansion of Clinical Indications Through Acquisition
2.10 Osiris Therapeutics
2.10.1 Osiris Therapeutics: Stem Cell Products
2.10.2 Osiris Therapeutics: Stem Cell Pipeline, 2014
2.10.3 Sales and Recent Performance, 2012
2.10.4 Osiris Therapeutics: Stem Cell SWOT Analysis, 2014-2024
2.10.5 Osiris Therapeutics: Stem Cell Revenue Forecast, 2014-2024
2.11 Other US Companies Operating in The Stem Cell Technology Industry, 2014

5. www.visiongain.com
Contents
3.1 Apceth
3.1.1 Apceth: Stem Cell Pipeline, 2014
3.1.1.1 Alecmestencel-T: Options for Autologous and Allogeneic Therapy
3.1.1.2 Agenmestencel-T: Genetically-modified Therapy for Cancer
3.1.2 Apceth: Stem Cell SWOT Analysis, 2014-2024
3.1.3 Apceth: Stem Cell Revenue Forecast, 2014-2024
3.2 Cardio3 BioSciences
3.2.1 Cardio3 BioSciences: Stem Cell Pipeline, 2014
3.2.1.1 C-Cure®: Creating New Muscle Cells
3.2.2 Cardio3 BioSciences: Stem Cell SWOT Analysis, 2014-2024
3.2.3 Cardio3 BioSciences: Stem Cell Revenue Forecast, 2014-2024
3.3 Cell Cure Neurosciences
3.3.1 Cell Cure Neurosciences: Stem Cell Pipeline, 2014
3.3.2 Cell Cure Neurosciences: Stem Cell SWOT Analysis, 2014-2024
3.4 TiGenix
3.4.1 Stem Cell Technology Platform
3.4.2 TiGenix: Stem Cell Products
3.4.2.1 ChondroCelect: One of Few Marketed Stem Cell Products
3.4.3 TiGenix: Stem Cell Pipeline, 2014
3.4.3.1 Cx601: Promoting Natural Close of Fissure
3.4.3.2 Cx611: Landmark Results of a Cell Therapy in Rheumatoid Arthritis
3.4.3.3 Cx621: Novel, Painless Route of Administration?
3. Top European and Israeli Stem Cell Technology Companies, 2014

6. www.visiongain.com
Contents
3.4.4 Sales and Recent Performance, 2012
3.4.5 TiGenix: Stem Cell SWOT Analysis, 2014-2024
3.4.6 TiGenix: Stem Cell Revenue Forecast, 2014-2024
3.5 Gamida Cell
3.5.1 Stem Cell Technology Platform
3.5.1.1 Copper Chelator-based Technology
3.5.1.2 Nicotinamide (NAM) Platform
3.5.2 Gamida Cell: Stem Cell Pipeline, 2014
3.5.2.1 StemEx: Huge Market Potential in Patient Numbers
3.5.2.2 NiCord: Transplanting Two Units of Umbilical Cord Blood
3.5.3 Gamida Cell: Stem Cell SWOT Analysis, 2014-2024
3.5.4 Gamida Cell: Stem Cell Revenue Forecast, 2014-2024
3.6 Pluristem Therapeutics
3.6.1 Stem Cell Technology Platform:
3.6.2 Pluristem Therapeutics: Stem Cell Pipeline, 2014
3.6.2.1 PLX-PAD: Clinical Hold Notification May Delay Approval
3.6.2.2 PLX-RAD: Accelerating Cell Engraftment in Bone Marrow Transplantation
3.6.3 US and Korea Licence Partnerships to Drive Revenue
3.6.4 Sales and Recent Performance, 2013
3.6.5 Pluristem Therapeutics: Stem Cell SWOT Analysis, 2014-2024
3.6.6 Pluristem Therapeutics: Stem Cell Revenue Forecast, 2014-2024
3.7 ReNeuron
3.7.1 ReNeuron: Stem Cell Technology Platform
3.7.2 ReNeuron: Stem Cell Pipeline, 2014
3.7.2.1 ReN001: Groundbreaking Therapy in Development

7. www.visiongain.com
Contents
3.7.2.2 ReN009: Avoiding Possible Limb Amputation
3.7.2.3 ReN003: Grant and Partnership with Leading US University Will Drive
Development
3.7.3 Sales and Recent Performance, 2013
3.7.4 ReNeuron: Stem Cell SWOT Analysis, 2014-2024
3.7.5 ReNeuron: Stem Cell Revenue Forecast, 2014-2024
3.8 Other European and Israeli Companies Operating in the Stem Cells Technology Industry, 2014
4.1 Anterogen
4.1.1 Anterogen: Stem Cell Products
4.1.1.1 Cupistem®: World’s First MSC Product From Adipose Tissue
4.1.1.2 Queencell®:
4.1.2 Anterogen: Stem Cell Pipeline, 2014
4.1.3 Anterogen: Stem Cell SWOT Analysis, 2014-2024
4.2 MEDIPOST
4.2.1 Stem Cell Technology Platform
4.2.2 MEDIPOST: Stem Cell Pipeline, 2014
4.2.2.1 Cartistem: A Top 25 Science Technology
4.2.2.2 Neurostem: Restorative Therapy For Neurological Disease
4.2.2.3 Pneumostem: Treatment for Paediatric Population
4.2.2.4 Promostem: Encouraging Engraftment of Cells Following Transplantation
4.2.3 Sales and Recent Performance, 2014
4.2.4 MEDIPOST: Stem Cell SWOT Analysis, 2014-2024
4.2.5 MEDIPOST: Stem Cell Revenue Forecast, 2014-2024
4. Top Asia-Pacific Stem Cell Technology Companies, 2014

8. www.visiongain.com
Contents
4.2.5.1 Collaboration with an Indian Company Expands Reach in Asia
4.3 Mesoblast
4.3.1 Stem Cell Technology Platform
4.3.2 Mesoblast: Stem Cell Pipeline, 2014
4.3.2.1 Immunology and Inflammatory Diseases
4.3.2.2 Spinal Disease
4.3.2.3 Cardiac and Vascular Disease
4.3.2.4 Oncology
4.3.2.5 Other Indications
4.3.3 Sales and Recent Performance, 2012
4.3.4 Mesoblast: Stem Cell SWOT Analysis, 2014-2024
4.3.5 Mesoblast: Stem Cell Revenue Forecast, 2014-2024
4.4 Pharmicell
4.4.1 Pharmicell: Stem Cell Products
4.4.1.1 Hearticellgram-AMI: World First Cell Therapy for Acute Myocardial Infarction
4.4.2 Pharmicell: Stem Cell Pipeline, 2014
4.4.3 Sales and Recent Performance, 2012
4.4.4 Pharmicell: Stem Cell SWOT Analysis, 2014-2024
4.4.5 Pharmicell: Stem Cell Revenue Forecast, 2014-2024
4.5 Stempeutics Research
4.5.1 Stem Cell Technology Platform
4.5.2 Stempeutics Research: Stem Cell Pipeline, 2014
4.5.2.1 Stempeucel®: Launch in Fast-Growing Asian Markets
4.5.2.2 Stempeucare™: Cosmetic Growth Factor Treatment
4.5.3 Stempeutics Research: Stem Cell SWOT Analysis, 2014-2024

9. www.visiongain.com
Contents
4.5.4 Stempeutics Research: Stem Cell Revenue Forecast, 2014-2024
4.5.4.1 Cipla Alliance to Drive Revenue as Wider Population Targeted
5.1 The World Stem Cell Technology Market, 2012
5.2 The World Stem Cell Technology Market: Revenue Forecast to 2024
5.2.1 What Will Drive The World Stem Cell Technology Market Between 2014 and 2024?
5.2.2 What Factors are Likely to Restrain the World Stem Cell Technology Market Between
2014 and 2024?
5.3 The Stem Cell Technology Market: Revenue Forecast by Therapeutic Application, 2014-2024
5.3.1 How Will Market Shares of Leading Stem Cell Therapeutic Applications Change from
2014-2024?
6.1 Strengths and Weaknesses of The Stem Cell Technologies Market
6.2 Strengths
6.2.1 Stem Cells Are Finally Proving Their Worth
6.3 Weaknesses
6.3.1 Many Difficulties Still to Overcome
6.4 Opportunities and Threats in the Stem Cell Technologies Market
6.4.1 Stem Cells Have Unprecedented Clinical Potential
6.4.2 Regulatory and Commercial Instability Threatens the Field
6.5 STEP Analysis of The Stem Cell Technologies Market, 2014-2024
6.5.1 Social Concerns: A Controversial Technology
5. The World Stem Cell Technology Market, 2014-2024
6. Stem Cell Technologies: Industry Trends, 2014-2024

10. www.visiongain.com
Contents
6.5.2 Technological Developments: Stem Cell Science Still on the March
6.5.3 Economic Factors: Funding Gaps a Concern
6.5.4 Political Issues: State Attitudes Vital to Research Environment
7.1 Dr Robin Smith: Chairman and CEO, NeoStem
7.1.1 The Potential of Stem Cell Therapy
7.1.2 Competition in The Stem Cell Arena
7.1.3 NeoStem’s Products and Technology
7.1.4 Concerns Over Stem Cell Therapy
7.1.5 Future Directions for NeoStem and Stem Cell Therapy
7.2 Dr Yael Margolin, President and CEO, Gamida Cell
7.2.1 Stem Cell Therapy and Their Therapeutic Promise
7.2.2 Gamida Cell’s NiCord Product and Umbilical Cord Blood
7.2.3 Partnership with a Leading Pharmaceutical Company
7.2.4 Barriers to Stem Cell Therapy Uptake
8.1 The US Leads the Field for Stem Cell Research
8.2 Market Remains Under-Capitalised, in Need of Financing
8.3 Many Barriers Still to Overcome for Companies
8.4 New Entrants to the Market Will Increase Competition
7. Opinions from Research Interviews
8. Conclusions

11. www.visiongain.com
Contents
About Visiongain’s Bespoke Research Service
Appendix A: About Visiongain
Appendix B: Visiongain Report Evaluation Form
Appendices

12. Page 41www.visiongain.com
Pharma Leader Series: Top Stem Cell
Technology Companies 2014-2024
2.3.3 Bioheart: Stem Cell SWOT Analysis, 2014-2024
Table 2.14 describes the main strengths, weaknesses, opportunities and threats of Bioheart and
their stem cell product portfolio. An important characteristic of Bioheart’s treatment approach is the
use of various cell types (rather than one particular type of cell). This offers a wider approach to
treatment and makes them more advantageous to treat a particular disease. Bioheart’s pipeline
candidates are still however in early clinical development and are unlikely to be launched until the
middle or end of our forecast period. Also, at the time of launch, the products may face strong
competition from well-established treatments, which at present are more advanced in clinical
development than Bioheart’s product. Furthermore, the company at present has limited funds to be
able to fully develop and commercialise their product alone. This may slow down their stem cell
programmes, unless Bioheart is able to establish partnerships or collaborations with other
companies more well-equipped.
With their focus on cardiovascular disease - specifically heart failure - Bioheart is targeting stem
cell therapies towards an indication where the incidence is expected to increase from 25 million
worldwide today to over 50 million in five years. If their clinical candidates receive market approval,
they have the potential to become a leading treatment for severe chronic damage to the heart, and
encouraging results thus far, support this statement. Also at present, Bioheart’s revenue generated
primary from sales of the MyoCath catheter product. The patent for this product expire in 2017.
After this time, competitors are free to sell products that incorporate same or similar technologies
as the MyoCath. This could substantially affect revenues for the company, thereby making it more
difficult to attract future investment in other pipeline candidates.
Strengths Weaknesses
Techology uses various cell types; rather than
one particular cell type used by rival companies.
Unliklely to lauch stem cell products in near
term future.
Stem cells are autologus (obtained from the
patient’s own body). Reduces risk of tissue
rejection need for immunosuppressive drugs
Limited funds and resources to conduct clinical
trials alone. Reliant on establishing and
maintaining effective strategic partnerships,
collaborations and licensing agreements.
Opportunities Threats
Therapies could revolutionise cardiovascular
disease treatment
Rival companies are more advanced with their
therapies in clinical development
Expansion of clinical sites in emerging countries
Patent on MyoCath (the company's only revenue-
generating product at present) expires 2017
No patent covering MyoCell
Table 2.14 Bioheart: Stem Cell SWOT Analysis, 2014-2024
Source: visiongain 2014

13. Page 42www.visiongain.com
Pharma Leader Series: Top Stem Cell
Technology Companies 2014-2024
2.3.4 Bioheart: Stem Cell Revenue Forecast, 2014-2024
Table 2.15 and Figure 2.6 shows the revenue forecast for Bioheart’s stem cell products during the
period 2014-2024. The most advanced pipeline candidate for Bioheart is MyoCell, which is in
phase II/II clinical development. Providing the company receives financial backing from
collaborators or partnerships, visiongain believes Bioheart plans to launch this drug in 2018, along
with other candidates following in later years. Visiongain predicts strong uptake of the company’s
products, as cardiovascular disease treatments are in high demand, and stem cell therapy could
be potentially a revolutionary treatment option in this field. Coupled with the vast patient population
that could be treated with this therapy, revenues for Bioheart’s products will reach $0.52m in 2024,
growing with a CAGR of 52.1% since 2018.
2012 2013 2014 2015 2016 2017 2018
Revenue ($m) 0.0 0.0 0.0 0.0 0.0 0.0 0.04
2019 2020 2021 2022 2023 2024
Revenue ($m) 0.09 0.18 0.30 0.40 0.48 0.52
Annual Growth (%) 114 100 67 33 20 8
CAGR (%, 2018-2024) 52.1
0.0
0.1
0.2
0.3
0.4
0.5
0.6
Revenue($m)
Year
Table 2.15 Bioheart: Stem Cell Revenue Forecast ($m, AGR %, CAGR %),
2013-2024
Figure 2.6 Bioheart: Stem Cell Revenue Forecast ($m), 2013-2024
Source: visiongain 2014
Source: visiongain 2014